Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 7 May 2025, 18:06 HKT/SGT
Share:
    

Source: Everest Medicines Limited
Everest Medicines Announces NMPA Full Approval of NEFECON, Broadening Treatment Access for IgA Nephropathy Patients in China

HONG KONG, May 7, 2025 - (ACN Newswire) - Everest Medicines (HKEX: 1952.HK) today announced that the supplemental New Drug Application (sNDA) for NEFECON has received full approval from the China National Medical Products Administration (NMPA). This regulatory milestone significantly broadens the treatment population, allowing NEFECON to be used to reduce the loss of kidney function in adult patients with primary immunoglobulin A nephropathy (IgAN) at risk of disease progression, regardless of proteinuria levels. The prior limitation requiring elevated proteinuria has now been removed.

With this latest approval, NEFECON becomes the first and only etiological treatment for IgAN to receive full approval in China, reaffirming its position as a foundational first-line therapy and marking a major advancement in the standard of care for IgAN patients.

"The full approval of NEFECON in China marks a significant milestone, providing a foundational first-line treatment for IgAN patients, regardless of proteinuria levels, and addressing critical unmet clinical needs," said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. "As the first and only etiological treatment for IgAN in China to receive full approval from the NMPA, this further reinforces NEFECON's proven clinical efficacy and safety, providing a solid foundation for treatment decision-making. With over 100,000 new cases diagnosed annually in China, there is a substantial unmet medical need. NEFECON's inclusion in the National Reimbursement Drug List (NRDL), with reimbursement now available in 31 provinces and cities, is key to improving accessibility and affordability for patients."

The NMPA's full approval is supported by robust efficacy and safety data from the global Phase 3 NefIgArd clinical trial, a randomized, double-blind, multicenter study evaluating NEFECON (16 mg once daily) compared with placebo in patients on optimized RASi therapy. In the global cohort, NEFECON demonstrated a statistically significant and clinically meaningful benefit in preserving estimated glomerular filtration rate (eGFR) over a two-year period-comprising 9 months of treatment and 15 months of follow-up off drug. NEFECON also showed durable reductions in urine protein creatinine ratio (UPCR) and a decline in microhematuria, further supporting its clinical utility.

In the China subpopulation of the Global Phase 3 NefIgArd Clinical Trial, NEFECON reduced the rate of kidney function decline by 66% and delayed the need for dialysis or kidney transplantation by 12.8 years, reinforcing its transformative potential for long-term disease management in Chinese patients.

As the first IgAN etiological treatment drug fully approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), NEFECON has been approved across all Everest Medicines territories, including mainland China, Hong Kong SAR, Macau SAR, Taiwan(China), as well as Singapore and South Korea. It is now commercially available in mainland China, Hong Kong, Macau, and Singapore, with anticipated launches in Taiwan(China), and South Korea later this year, benefiting IgAN patients in all authorized regions.

The full approval of NEFECON not only broadens its clinical applicability, allowing more IgAN patients to benefit from targeted therapy earlier in their disease progression, but also represents a significant advancement in Everest Medicines leadership in the renal disease sector. This milestone further demonstrates Everest's dedication to accelerating access to innovative treatments that address critical unmet medical needs and provide long-term value for patients, healthcare systems, and society.




Topic: Press release summary
Source: Everest Medicines Limited

Sectors: BioTech, Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Everest Medicines Limited
Apr 22, 2025 10:16 HKT/SGT
Everest Medicines Announces Approval of 'B' Marker Removal from Company's Stock Code by the Hong Kong Stock Exchange
Mar 7, 2025 19:30 HKT/SGT
Everest Medicines Hits Three-Year High as AI+mRNA Pipeline Reshapes Valuation
Feb 19, 2025 14:42 HKT/SGT
Goldman Sachs Raises Everest Medicines' Target Price to HK$48.32 on Stronger Commercial and R&D Outlook
Jan 2, 2025 10:52 HKT/SGT
Everest Medicines Announces the Implementation of NEFECON National Reimbursement Drug List Pricing in China for the Treatment for IgA Nephropathy
Dec 18, 2024 14:29 HKT/SGT
Everest Medicines Announces the First Prescription of VELSIPITY(R) in the Greater Bay Area
Dec 17, 2024 10:58 HKT/SGT
Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY
Dec 12, 2024 12:11 HKT/SGT
Everest Medicines Announces the First Prescription of VELSIPITY(R) Issued in Macau
Dec 11, 2024 11:06 HKT/SGT
Everest Medicines: Accelerating Innovation in Renal Disease to Forge a Path Toward Biopharma Leadership
Dec 4, 2024 11:08 HKT/SGT
Everest Medicines Announces Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of EVER001, a Novel BTK Inhibitor for the Treatment of Primary Membranous Nephropathy
Dec 2, 2024 10:34 HKT/SGT
Everest Medicines Announces Acceptance of VELSIPITY New Drug Application in Hong Kong
More news >>
 News Alerts
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: